Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Antibodies are the workhorses of biological experiments, but they are littering the field with false findings. A few evangelists are pushing for change.
Thirty years of pursuit have failed to yield a drug to take on one of the deadliest families of cancer-causing proteins. Now some researchers are taking another shot.
Swiss-cheese-like materials called metal–organic frameworks have long promised to improve gas storage, separation and catalysis. Now they are coming of age.
Transfusions are one of the most overused treatments in modern medicine, at a cost of billions of dollars. Researchers are working out how to cut back.
US funding agencies are turning to a Silicon Valley entrepreneur to focus fledgling biomedical companies on success — even when that means making a scientific course correction.